Physician profile
Sasikanth Adigopula
NPI 1053325050
$310,238.80
in general payments reported to CMS, 2019-2025
25 companies · $118K in 2025
The $118K reported for 2025 was more than what 98% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $6,707 · 2021: $7,909 · 2022: $7,592 · 2023: $68K · 2024: $101K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $254K · Travel and Lodging: $21K · Food and Beverage: $6,487 · Consulting Fee: $5,450 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $254,150.00 |
| Travel and Lodging | $21,387.43 |
| Food and Beverage | $6,487.35 |
| Consulting Fee | $5,450.00 |
| Education | $183.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $130,351.58 | 2022-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $54,164.82 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals Lp | $42,414.15 | 2020-2024 | Farxiga, Lokelma, Wainua |
| United Therapeutics Corporation | $41,242.92 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Lilly USA, LLC | $21,185.47 | 2023-2025 | Jardiance |
| Abbott Laboratories | $11,467.63 | 2019-2025 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Scpharmaceuticals INC. | $7,850.00 | 2024 | |
| Boston Scientific Corporation | $327.32 | 2019-2024 | Watchman Flx, Ranger |
| Cvrx, INC. | $186.03 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $152.20 | 2024-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $132.12 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $130.00 | 2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $108.80 | 2019 | |
| Abiomed | $99.63 | 2024 | |
| Livanova USA, INC. | $90.97 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $70.95 | 2019-2024 | |
| Amgen INC. | $70.83 | 2019 | |
| Pfizer INC. | $47.15 | 2022-2023 | |
| Bridgebio Pharma, INC. | $43.92 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $31.14 | 2022-2025 | |
| Atricure, INC. | $23.15 | 2025 | Synergy Ablation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.89 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $16.67 | 2024 | Arcalyst |
| Hologic Sales and Service, LLC | $13.46 | 2025 | Acessa Provu System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasikanth Adigopula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.